Clinical impacts of copy number variations in B-cell differentiation and cell cycle control genes in pediatric B-cell acute lymphoblastic leukemia: a single centre experience

被引:8
|
作者
Crepinsek, Klementina [1 ,2 ]
Marinsek, Gasper [1 ]
Kavcic, Marko [2 ,3 ]
Prelog, Tomaz [3 ]
Kitanovski, Lidija [3 ]
Jazbec, Janez [2 ,3 ]
Debeljak, Marusa [1 ,2 ]
机构
[1] Univ Med Ctr Ljubljana, Univ Childrens Hosp, Clin Inst Special Lab Diagnost, Vrazov Trg 1, Ljubljana 1000, Slovenia
[2] Univ Ljubljana, Fac Med, Ljubljana, Slovenia
[3] Univ Med Ctr Ljubljana, Univ Childrens Hosp, Dept Oncol & Haematol, Ljubljana, Slovenia
关键词
B-acute lymphoblastic leukemia; IKZF1; deletions; IKZF1(plus); MLPA; pediatric; copy number variations (CNVs); IKZF1; DELETION; IKAROS GENE; PROGNOSTIC MARKER; POOR-PROGNOSIS; PRECURSOR; CHILDHOOD; CHILDREN; PAX5; STRATIFICATION; CLASSIFICATION;
D O I
10.2478/raon-2021-0050
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background IKZF1 gene deletions have been identified as a poor prognostic factor in pediatric B-cell acute lymphoblastic leukemia (B-ALL), especially in the presence of co-occurring deletions (IKZF1(plus) profile). This study aimed to determine the frequency of IKZF1 deletions and deletions in other B-cell differentiation and cell cycle control genes, and their prognostic impact in Slovenian pediatric B-ALL patients. Patients and methods We studied a cohort of 99 patients diagnosed with B-ALL from January 2012 to December 2020 and treated according to the ALL IC-BFM 2009 protocol. Eighty-eight bone marrow or peripheral blood samples were analysed for copy number variations (CNVs) using the SALSA MLPA P335 ALL-IKZF1 probemix. Results At least one CNV was detected in more than 65% of analysed samples. The most frequently altered genes were PAX5 and CDKN2A/B (30.7%, 26.1%, and 25.0%, respectively). Deletions in IKZF1 were present in 18.2% of analysed samples and were associated with an inferior 5-year event-free survival (EFS; 54.8% vs. 85.9%, p = 0.016). The IKZF1(plus) profile was identified in 12.5% of the analysed samples, and these patients had an inferior 5-year EFS than those with deletions in IKZF1 only and those without deletions (50.8% vs. 75.0% vs. 85.9%, respectively, p = 0.049). Overall survival (OS) was also worse in patients with the IKZF1(plus) profile than those with deletions in IKZF1 only and those without deletions (5-year OS 76.2% vs. 100% vs. 93.0%, respectively). However, the difference between the groups was not statistically significant. Conclusions Our results are in concordance with the results obtained in larger cooperative clinical trials. Copy number variations analysis using the SALSA MLPA kit is a reliable tool for initial diagnostic approach in children with B-ALL, even in smaller institutions in low- and middle-income countries.
引用
收藏
页码:92 / 101
页数:10
相关论文
共 50 条
  • [41] Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges
    Jasinski, Sylwia
    De Los Reyes, Francis Andrew
    Yametti, Gloria Contreras
    Pierro, Joanna
    Raetz, Elizabeth
    Carroll, William L.
    PEDIATRIC DRUGS, 2020, 22 (05) : 485 - 499
  • [42] Reviving exhausted T cells in pediatric B-cell acute lymphoblastic leukemia
    Atre, Tanmaya
    Reid, Gregor S. D.
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
  • [43] Genetic Profiling of Pediatric Patients with B-Cell Precursor Acute Lymphoblastic Leukemia
    Akin-Bali, Dilara Fatma
    Erdogan, Beyza Doganay
    Oner, Deniz Aslar
    Mahmud, Akkan
    Tasdelen, Serpil
    Kurekci, Emin
    Akar, Nejat
    Sevgili, Hilal Ozdag
    JOURNAL OF PEDIATRIC GENETICS, 2023, 12 (04) : 288 - 300
  • [44] Implications of mitochondrial DNA variants in pediatric B-cell acute lymphoblastic leukemia
    Ayushi Jain
    Amit Katiyar
    Ritika Singh
    Sameer Bakhshi
    Harpreet Singh
    Jayanth Kumar Palanichamy
    Archna Singh
    Egyptian Journal of Medical Human Genetics, 23
  • [45] Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges
    Sylwia Jasinski
    Francis Andrew De Los Reyes
    Gloria Contreras Yametti
    Joanna Pierro
    Elizabeth Raetz
    William L. Carroll
    Pediatric Drugs, 2020, 22 : 485 - 499
  • [46] Implications of mitochondrial DNA variants in pediatric B-cell acute lymphoblastic leukemia
    Jain, Ayushi
    Katiyar, Amit
    Singh, Ritika
    Bakhshi, Sameer
    Singh, Harpreet
    Palanichamy, Jayanth Kumar
    Singh, Archna
    EGYPTIAN JOURNAL OF MEDICAL HUMAN GENETICS, 2022, 23 (01)
  • [47] GENOMIC ALTERATIONS OF KOREAN PEDIATRIC PATIENTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
    Kim, Hyerin
    Kim, In-Suk
    Lee, Jeong Nyeo
    Hyun, Ju Kyung
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2023, 45 : 84 - 84
  • [48] New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia
    Lilljebjorn, Henrik
    Fioretos, Thoas
    BLOOD, 2017, 130 (12) : 1395 - 1401
  • [49] Expression and Clinical Significance of Spi-B in B-cell Acute Lymphoblastic Leukemia
    Ariga, Yuzuru
    Low, Shulin
    Hoshino, Hitomi
    Nakada, Tsutomu
    Akama, Tomoya O.
    Muramoto, Akifumi
    Fukushima, Mana
    Yamauchi, Takahiro
    Ohshima, Yusei
    Kobayashi, Motohiro
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2022, 70 (10) : 683 - 694
  • [50] Benchmarking miRNA reference genes in B-cell precursor acute lymphoblastic leukemia
    Mack, Teresa
    Gianferri, Tommaso
    Niedermayer, Alexandra
    Debatin, Klaus-Michael
    Meyer, Luder H.
    Muench, Vera
    SCIENTIFIC REPORTS, 2024, 14 (01):